share_log

Strong Week for AdaptHealth (NASDAQ:AHCO) Shareholders Doesn't Alleviate Pain of Three-year Loss

Strong Week for AdaptHealth (NASDAQ:AHCO) Shareholders Doesn't Alleviate Pain of Three-year Loss

對adapthealth(納斯達克:AHCO)股東而言,強勁的一週並不能減輕三年虧損的痛苦
Simply Wall St ·  11/26 22:26

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the risk of stock picking is that you will likely buy under-performing companies. Unfortunately, that's been the case for longer term AdaptHealth Corp. (NASDAQ:AHCO) shareholders, since the share price is down 50% in the last three years, falling well short of the market return of around 25%. But it's up 5.7% in the last week.

爲了證明選擇個股的努力是有價值的,值得努力超越市場指數基金的回報。但選股的風險在於你可能會購買表現不佳的公司。不幸的是,這對於長期的adapthealth公司(納斯達克:AHCO)股東來說一直是個問題,因爲股價在過去三年中下跌了50%,遠遠低於大約25%的市場回報。然而,在過去一週中股價上漲了5.7%。

While the last three years has been tough for AdaptHealth shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.

儘管過去三年對adapthealth股東而言很艱難,但上週顯示出了一些希望。因此,讓我們看看長期的基本面,看看它們是否是負回報的驅動因素。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

在他的文章《格雷厄姆和道德斯維爾的超級投資者》中,禾倫·巴菲特描述了股價並不總是理性反映公司價值的方式。檢查市場情緒如何隨時間變化的一種方式是查看公司股價與每股收益(EPS)之間的互動。

We know that AdaptHealth has been profitable in the past. On the other hand, it reported a trailing twelve months loss, suggesting it isn't reliably profitable. Other metrics might give us a better handle on how its value is changing over time.

我們知道adapthealth過去是盈利的。另一方面,它報告了過去十二個月的虧損,這表明它並不可靠地盈利。其他指標可能會讓我們更好地了解其價值隨時間的變化。

Revenue is actually up 11% over the three years, so the share price drop doesn't seem to hinge on revenue, either. It's probably worth investigating AdaptHealth further; while we may be missing something on this analysis, there might also be an opportunity.

營業收入在過去三年中實際上增長了11%,因此股價下跌似乎並不依賴於營業收入。可能值得進一步調查adapthealth;儘管我們可能在這次分析中遺漏了一些東西,但也可能存在機會。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。

big
NasdaqCM:AHCO Earnings and Revenue Growth November 26th 2024
納斯達克CM:AHCO 每股收益和營業收入增長 2024年11月26日

This free interactive report on AdaptHealth's balance sheet strength is a great place to start, if you want to investigate the stock further.

這份關於adapthealth資產負債表強度的免費互動報告是一個很好的開始,如果你想進一步研究這隻股票。

A Different Perspective

另一種看法

AdaptHealth provided a TSR of 16% over the last twelve months. But that return falls short of the market. The silver lining is that the gain was actually better than the average annual return of 1.1% per year over five year. This could indicate that the company is winning over new investors, as it pursues its strategy. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with AdaptHealth .

adapthealth在過去十二個月提供了16%的總股東回報率。但這一回報低於市場。幸運的是,這一收益實際上優於過去五年年均1.1%的回報。這可能表明該公司正在贏得新的投資者,因爲它在追求其策略時表現出色。雖然考慮市場狀況對股票價格的不同影響是值得的,但還有其他因素更爲重要。爲此,你應該知道我們發現的adapthealth的一個警告信號。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,您可能通過在其他地方尋找會找到一筆極好的投資。因此,請查看我們預計會增長收入的公司免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論